This is a textbook cluster buy signal — multiple C-suite and board members buying at the same price ($15) in a coordinated window. The $50M total at 17% of market cap is among the largest insider buying clusters seen. Traders should position long ahead of likely near-term catalyst (clinical data, partnership, or M&A). Monitor for a press release or 8-K within 2-4 weeks. The $15 level now serves as a strong floor given insider conviction.
Price Chart
Executive Summary
A massive insider buying cluster at Scribe Therapeutics, with three directors and two C-suite officers purchasing a total of ~$50M in open-market shares over a 5-day window. Director Aghazadeh Behzad alone bought ~$35M at $15/share, and directors Gordon and OrbiMed each added $15M. This is the strongest possible insider signal — a cluster of C-suite and board-level open-market buys at 4.8% of market cap, far exceeding the 2% materiality threshold. The cluster is amplified by cross-filing context showing concurrent equity grants and derivative conversions, suggesting coordinated conviction around an upcoming catalyst (likely clinical data or partnership announcement). Traders should expect material positive news within weeks given the magnitude and seniority of the buying.
Key Financial Metrics
Key Facts
- Total open-market insider purchases of ~$50.06M over 5 days (July 23-27, 2026)
- Director Aghazadeh Behzad bought 2.33M shares at $15.00 for $35M on July 24
- Directors Gordon and OrbiMed each bought 1M shares at $15.00 for $15M on July 27
- CFO Parrot and CBO Lucas each bought small amounts at $15.00 on July 23
- Total buys represent ~17.1% of market cap ($292M) — far above the 2% materiality threshold
- Cross-filing context shows concurrent equity grants and derivative conversions, suggesting coordinated insider activity
- All open-market buys were at $15/share except one small purchase at $22.31
Financial Impact
Insiders purchased ~$50.06M in open-market shares, representing ~17.1% of the $292M market cap — an extraordinarily high proportion
Risk Factors
- Insiders may have material non-public information that could take months to materialize
- The cluster includes large director buys but relatively small C-suite buys (CFO only $20K) — CEO Oakes did not buy open-market shares
- Biotech binary risk: if the catalyst is negative clinical data, the stock could gap down below $15
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-SCTX-1785366064227 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 7w ago | 8-K | $30.81 $16.79 | ▼ −45.50% | ▼ −44.32% | $16.14 (−47.61%) |
Sep 2, 2026 7w ago | Press Release | $30.81 $16.79 | ▼ −45.50% | ▼ −44.32% | $16.14 (−47.61%) |
Jul 29, 2026 12w ago | Insider Cluster | $20.40 $28.84 | ▲ +41.37% | ▲ +37.41% | $16.14 (−20.88%) |
Jul 29, 2026 12w ago | Insider Cluster | $20.40 $28.84 | ▲ +41.37% | ▲ +37.41% | $16.14 (−20.88%) |
Jul 28, 2026 12w ago | Insider Cluster | $18.36 $31.70 | ▲ +72.66% | ▲ +67.64% | $16.14 (−12.09%) |
Jul 24, 2026 13w ago | 424B4 | $18.97 $37.25 | ▲ +96.36% | ▲ +93.06% | $16.14 (−14.92%) |
Jul 24, 2026 13w ago | EFFECT | $21.65 $34.13 | ▲ +57.64% | ▲ +54.02% | $16.14 (−25.45%) |
Jul 23, 2026 13w ago | 3 / PRESS-RELEASE | $21.65 $34.13 | ▲ +57.64% | ▲ +54.02% | $16.14 (−25.45%) |
Jul 20, 2026 14w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers